利用选择基因驱动克服耐药肿瘤。
Overcoming drug-resistant tumors with selection gene drives.
机构信息
Research Center for Life Sciences Computing, Zhejiang Lab, Hangzhou 311100, Zhejiang, China.
School of Medicine, Westlake University, Hangzhou 310024, Zhejiang, China; Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, Zhejiang, China; Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310024, Zhejiang, China; School of Engineering, Westlake University, Hangzhou 310030, Zhejiang, China.
出版信息
Cell Genom. 2024 Sep 11;4(9):100653. doi: 10.1016/j.xgen.2024.100653.
Drug resistance is a major hurdle prohibiting effective treatment of many diseases, including cancer. Using model-guided designs, Leighow et al. engineered a dual-switch selection gene drive system custom designed to combat drug-resistant tumors. By demonstrating remarkable killing efficacies in preclinical models using human non-small lung cancer cells in vitro and in mice, this work describes an attractive mindset to develop next-generation anticancer therapies.
耐药性是阻碍许多疾病（包括癌症）有效治疗的主要障碍。Leighow 等人使用模型指导设计，设计了一种双开关选择基因驱动系统，专门用于对抗耐药性肿瘤。通过在体外使用人类非小细胞肺癌细胞和在小鼠中进行的临床前模型中证明了显著的杀伤效果，这项工作描述了一种有吸引力的思维方式，以开发下一代抗癌疗法。
Zotero 插件